Clinical trials: Rejection Heart Transplant
Congenital Disorders
Daclizumab Experience in Pediatric Heart Transplant
The purpose of this study is to examine the outcomes of those who have received Daclizumab as part of their immuno-suppression protocol following heart transplantation.
- Trial name
- NCT00486057
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Healthcare of Atlanta
Heart Transplant Recipient
HEART-BC: Heart Transplant Evaluation Using Advanced Rejection Monitoring Tools - British Columbia
Evaluate whether integration of HeartCare (AlloMap + AlloSure) into routine post-transplant surveillance reduces the number of invasive endomyocardial biopsies (EMBx) in the first year post-transplant
- Trial name
- HEART-BC (NCT07819292)
- Volunteers
- 30 people
- Sponsor
- Cardiology Research UBC
Heart Transplant Failure and Rejection, Coronary Artery Disease
Percutaneous Coronary Intervention in Patients witH OrthotoPic hEart Transplantation: the PCI-HOPE a Multicenter Study.
This is a retrospective, multicenter, study including patients undergone to one or more percutaneous revascularization after OHT.
- Trial name
- PCI-HOPE (NCT03538509)
- Testing
- PCI and implantation drug eluting stent or bare metal stent
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Fabrizio D'Ascenzo
Heart Transplanted Patients, Lung Transplanted Patients
Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients
This is a prospective observational single center national study. Lung and heart transplant patients with a definite diagnosis of chronic lung allograft dysfunction (CLAD) or cardiac allograft vasculopathy (CAV) will be assigned…
- Conditions
- Heart Transplanted Patients, Lung Transplanted Patients, Chronic Lung Allograft Dysfunction (CLAD), Cardiac Allograft Vasculopathy
- Trial name
- URRAH (NCT06899828)
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Transplant Failure and Rejection
A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy
This is an open label Comparative Effectiveness Research (CER) study in which patients will be randomized at the site level to Prospera surveillance or EMB surveillance in a 2:1 ratio (Prospera to EMB) at each site.
- Trial name
- ACES-EMB (NCT06414603)
- Testing
- The Prospera™ Test
- Where
- 16 sites in United States
- Volunteers
- 250 people
- Sponsor
- Natera, Inc.
Heart Transplant Failure and Rejection
Bioelectrical Impedance Spectroscopy in Heart Transplantation: Tracking Post-Transplant Changes in Body Composition and Correlation With Conventional Preoperative Risk Assessment Modalities
Patients with marginal physiologic reserve, severe frailty, and/or malnutrition may be regarded as unsuitable candidates for advanced cardiac replacement therapies.
- Trial name
- BIS (NCT03373279)
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Baylor Research Institute
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation.
- Trial name
- NCT01848301
- Testing
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gladwin, Mark, MD
Heart Transplantation, Kidney Transplantation
Effects of Donor and Recipient Genetic Expression on Heart, Lung, Liver, or Kidney Transplant Survival
Activity of genes in donor tissues that are involved in inflammation are thought to be involved with early organ dysfunction, increased immune responses in transplant recipients, and organ rejection.
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation, Lung Transplantation
- Trial name
- NCT00531921
- Where
- 5 sites in United States
- Volunteers
- 313 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cardiac Failure, Graft Rejection
OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels
This study aims to develop and refine a microRNA (miR) biomarker panel that can be used to phenotype net immune state after heart transplantation using circulating miRs (associated with drug doses and levels).
- Trial name
- OPTIMAL (NCT06939751)
- Where
- 6 sites in United States
- Volunteers
- 250 people
- Sponsor
- Northwestern University
Cardiac Allograft Vasculopathy, Heart Transplant Rejection
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV).
- Trial name
- ECP-OCT (NCT04226521)
- Testing
- Extracoropreal photopheresis
- Where
- Croatia
- Volunteers
- 38 people
- Sponsor
- Bosko Skoric
Disorder Related to Cardiac Transplantation
Heart Transplant Registry of Városmajor
The purpose of this registry is to determine the long term outcomes of heart transplantations performed at the Semmelweis University Heart and Vascular Center.
- Trial name
- NCT02347371
- Where
- Hungary
- Volunteers
- 11 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Heart Transplantation
A Study of Daclizumab (Zenapax) in Combination With Mycophenolate Mofetil (CellCept) and Sirolimus in Prevention of Acute Rejection in Heart Transplant Participants
This study will evaluate the efficacy and safety of intravenous daclizumab in combination with oral mycophenolate mofetil and oral sirolimus in participants receiving a heart transplant, and at risk of impaired kidney function.
- Trial name
- NCT02554955
- Testing
- Daclizumab, Mycophenolate mofetil, Silrolimus
- Where
- 14 sites in Spain
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Heart-lung Transplant Rejection
Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction
The aim of the study is to compare optimal medical therapy alone versus percutaneous coronary intervention on top of medical therapy in the setting of heart transplant recipient coronary artery disease in a randomized trial.The…
- Trial name
- ARCHER (NCT01795729)
- Testing
- Stent, optimal medical therapy
- Where
- France
- Volunteers
- 6 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Chronic Rejection of Cardiac Transplant
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
The different mechanisms of action of Everolimus and cyclosporine suppress immune function in synergistic manner. Thus it is postulated that the use of Everolimus in combination with cyclosporine permits a significant…
- Trial name
- CRAD001AILO2 (NCT00596557)
- Testing
- everolimus
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Acute Cellular Graft Rejection, Cardiac Sarcoidosis
[68Ga]Ga-PentixaFor PET/CT in Acute Myocardial Inflammation
Acute myocardial inflammation is an heterogenic syndrome involving different clinical pathologies with different outcome. For the purpose of this study protocol, we focuse on three entities of this syndrome, namely the acute…
- Conditions
- Acute Cellular Graft Rejection, Cardiac Sarcoidosis, Myocarditis Due to Drug
- Trial name
- NCT05499637
- Testing
- [68Ga]Ga-PentixaFor PET/CT
- Where
- Switzerland
- Volunteers
- 25 people
- Sponsor
- John O. Prior
Cardiac Transplant Rejection
A Study of AI in Cardiac Transplant in Echocardiographic Analysis (ORACLE)
The purpose of this research is to detect episodes of rejection versus non-rejection after cardiac transplant and the diagnostic accuracy of an Artificial Intelligence (AI) algorithm using the data from an ECG (electrocardiogram)…
- Trial name
- ORACLE (NCT06178744)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Mayo Clinic
Cardiac Transplant Disorder, Cardiac Death
HEart trAnsplantation Registry of piTie-Salpetriere University Hospital
Heart transplantation (HTx) is a procedure which is hindered by several complications. The HEARTS registry aims to allow the analysis of risk factors of all post-HTx complications.
- Conditions
- Cardiac Transplant Disorder, Cardiac Death, Heart Failure, Acute Cellular Graft Rejection
- Trial name
- HEARTS (NCT03393793)
- Volunteers
- 566 people
- Sponsor
- Lee S Nguyen
Heart Transplantation, Kidney Transplantation
A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time
The purpose of this study is to compare how the body absorbs and processes two different formulations of the anti-rejection medication tacrolimus (Advagraf® or Prograf®) in children receiving an organ transplant, and how safe and…
- Conditions
- Heart Transplantation, Kidney Transplantation, Liver Transplantation
- Trial name
- NCT01614665
- Testing
- Tacrolimus, Tacrolimus prolonged release
- Where
- 10 sites in Czechia, France and 3 more
- Volunteers
- 44 people
- Sponsor
- Astellas Pharma Europe Ltd.
Heart Transplantation
Study of Heart Transplant Rejection
This study will investigate the causes of acute and chronic rejection of transplanted hearts. To find better ways to detect, treat and possibly prevent heart transplant rejection, more information about the cause is needed.
- Trial name
- NCT00042614
- Where
- 2 sites in United States
- Volunteers
- 188 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Heart Transplant Rejection
Donor-derived Cell Free DNA as a New Biomarker in Cardiac Acute Rejection
FreeDNA-CAR is a prospective, observational multicenter study, that will include a total of 200 adult heart transplant (HT) patients from 14 centers in Spain.
- Trial name
- FreeDNA-CAR (NCT04973943)
- Testing
- Donor-derived cell Free DNA
- Where
- 12 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Puerta de Hierro University Hospital